Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
A phase 3 trial of Carfilzomib, Pomalidomide, Elotuzumab in multiple myeloma, run by AbbVie, active and no longer recruiting.
Overview
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06158841 by AbbVie, with 421 participants enrolled, started 2024-05-19 and due to reach its primary completion in 2027-12. Interventions recorded: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Elotuzumab, Carfilzomib, Pomalidomide, Bortezomib.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Selinexor, Pomalidomide, Bortezomib, Dexamethasone.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
- TrialStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Shares Carfilzomib, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.